1. Home
  2. ZYME vs IDT Comparison

ZYME vs IDT Comparison

Compare ZYME & IDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.58

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

HOLD

Current Price

$49.46

Market Cap

1.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
IDT
Founded
2003
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
ZYME
IDT
Price
$26.58
$49.46
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
1.9M
131.9K
Earning Date
11-06-2025
12-04-2025
Dividend Yield
N/A
0.48%
EPS Growth
N/A
18.50
EPS
N/A
3.01
Revenue
$134,481,000.00
$1,231,495,000.00
Revenue This Year
$65.21
$0.77
Revenue Next Year
$20.39
N/A
P/E Ratio
N/A
$16.53
Revenue Growth
116.21
2.13
52 Week Low
$9.03
$44.77
52 Week High
$28.49
$71.12

Technical Indicators

Market Signals
Indicator
ZYME
IDT
Relative Strength Index (RSI) 73.43 44.56
Support Level $21.89 $49.36
Resistance Level $28.49 $52.45
Average True Range (ATR) 1.53 1.23
MACD 0.65 0.05
Stochastic Oscillator 84.61 37.87

Price Performance

Historical Comparison
ZYME
IDT

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

Share on Social Networks: